Intuitive

Stryker and CMR Surgical said in a joint press release on Oct 12 that Stryker will make a preferred equity investment of about $400 million (£300 million) in the Cambridge, England, surgical robot maker, a stake that also gives Stryker an exclusive option to acquire 100% of CMR's equity later on terms the companies did not disclose. Stryker becomes the exclusive U.S. sales agent for the Versius soft-tissue robot, while CMR keeps development and commercialisation outside the United States, and Stryker's Group President for Medsurg and Neurotechnology, Andy Pierce, joins CMR's board. Pierce said Stryker had studied soft-tissue robotics for years and chose Versius for its fit in hospitals and ambulatory surgery centres; the deal still needs regulatory approvals and customary closing conditions. In MEKAWIRE's funding records, CMR's last disclosed priced amount was a $600 million Series D in June 2021, and its April 2025 equity-and-debt package carries no disclosed figure, so Stryker's cheque is the largest disclosed inflow into the company in five years.

EndoRobotics said in a press release on Oct 6 that Korea's trade ministry (MOTIR) determined on Oct 1 that the core technology of its ROBOPERA flexible endoscopic surgical robot falls under the National Core Technology framework, in the category covering design, manufacturing and control of laparoscopic, endoscopic and image-guided surgical robots. National Core Technology is designated and managed by the government under the Act on Prevention of Divulgence and Protection of Industrial Technology, the release noted. ROBOPERA attaches robotic instruments to a standard endoscope so gastrointestinal lesions can be removed through the mouth or anus without an incision; it received FDA 510(k) clearance in 2025, and the company said it signed an exclusive global distribution deal with Olympus in May 2026 and is in final preparations for a U.S. launch in the second half of 2026. EndoRobotics is the first Korean endoscopic surgery robot maker in MEKAWIRE's database, where Intuitive Surgical anchors the surgical-robot category.

Intuitive placed 468 da Vinci systems in the second quarter of 2026, up from 395 a year earlier, including 246 da Vinci 5 units, and revenue rose 19% to $2.89 billion, the company said on 16 July. It lifted its 2026 non-GAAP gross margin outlook to 68% to 69% of revenue, the second increase this year, while holding da Vinci procedure growth guidance at 13.5% to 15.5% and pointing to the midpoint.

Shanghai MicroPort MedBot said revenue rose 114.2% to RMB551.1 million in 2025, with overseas sales of RMB400.2 million accounting for 73% of the total. The Hong Kong-listed surgical robot maker cut its net loss by 60.7% to RMB254.1 million as cumulative orders for its Toumai laparoscopic robot reached about 220 units.

Intuitive reported on January 22, 2026 that 2025 revenue rose about 21% to $10.06 billion as surgeons performed 3.153 million da Vinci procedures, and da Vinci 5 made up 870 of the 1,721 systems it placed. The company guided 2026 da Vinci procedure growth to 13% to 15%, down from about 18%, and put the tariff cost to its gross margin at about 1.2% of revenue.

Shenzhen Edge Medical raised HK$1,198.7 million in a Hong Kong IPO priced at HK$43.24 a share and began trading on 8 January 2026, with the retail tranche 1,091.94 times subscribed. Its first annual results showed revenue up 184.8% to RMB455.7 million and 50 of 72 robots delivered in 2025 going overseas.

Johnson & Johnson has submitted its Ottava soft-tissue surgical robot to the US Food and Drug Administration in a De Novo classification request covering several upper abdominal procedures, backed by a 32-patient gastric bypass study at six US hospitals. The filing comes weeks after Medtronic and CMR Surgical won US clearances, widening the field challenging Intuitive's 10,763-system da Vinci base.

The FDA cleared Medtronic's Hugo robotic-assisted surgery system for prostatectomy, nephrectomy and cystectomy on December 3, 2025, after a 268-day 510(k) review. The clearance rests on the 137-patient Expand URO study, which reported a 98.5% surgical success rate, and gives Medtronic its first US entry against Intuitive's da Vinci after years of selling Hugo in more than 30 other countries.

Swiss surgical robot maker Distalmotion closed a US$150 million Series G led by Revival Healthcare Capital on 18 November 2025 and named former Silk Road Medical chief executive Chas McKhann executive chairman. Johnson & Johnson's venture arm followed with a strategic investment in January 2026, and by August the FDA had cleared DEXTER for five procedures aimed at ambulatory surgery centres.